申请人:KINDEX PHARMACEUTICALS, INC.
公开号:US10343977B2
公开(公告)日:2019-07-09
The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.
本申请提供了新型四氢异胡麻酮(THIAA)衍生物及其对映体纯度高的组合物和药物制剂。本申请进一步提供了使用所公开的化合物和组合物激活 PPARγ、抑制炎症、治疗与炎症相关的病症和对 PPARγ 调节有反应的病症(如糖尿病)的方法。